article Open AccessTop 1% cited
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Journal of the American Academy of Dermatology · 2015 · Vol. 73(3) · pp. 400–409
Diamant Thaçi✉(University Hospital Schleswig-Holstein)Andrew Blauvelt(Oregon Medical Research Center)Kristian Reich(University of Göttingen)Tsen‐Fang Tsai(National Taiwan University Hospital)F. Vanaclocha(Research Institute Hospital 12 de Octubre)Külli Kingo(University of Tartu)Michael Ziv(Emek Medical Center)Andreas Pinter(Goethe University Frankfurt)Sophie Hugot(Novartis (Switzerland))R. You(Novartis (Switzerland))M. Milutinovic(Novartis (Switzerland))
Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesAutoimmune Bullous Skin DiseasesSecukinumabUstekinumabMedicinePsoriasis Area and Severity IndexDermatology Life Quality IndexPsoriasisPlaceboRandomized controlled trialAdverse effectDermatology
MeSH terms
UstekinumabAdultAnalysis of VarianceAntibodies, MonoclonalDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansInjections, SubcutaneousMaleMiddle AgedPsoriasisReference Values
Funding
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen
- Celgene
- Galderma
- LEO Pharma
- Cilag
Citations
538
FWCI
30.44
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
Psoriasis Pathogenesis and Treatment
International Journal of Molecular Sciences · 2019 · 1,924 citations
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Journal of the American Academy of Dermatology · 2019 · 880 citations
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Journal of the American Academy of Dermatology · 2018 · 631 citations
Psoriasis pathogenesis and the development of novel targeted immune therapies
Journal of Allergy and Clinical Immunology · 2017 · 915 citations
References
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
British Journal of Dermatology · 2013 · 406 citations
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Journal of the American Academy of Dermatology · 2007 · 872 citations
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Science Translational Medicine · 2010 · 858 citations
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
British Journal of Dermatology · 2005 · 692 citations
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
British Journal of Dermatology · 2007 · 720 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.